GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (OTCPK:NNCSF) » Definitions » Cash-to-Debt

Nanosonics (Nanosonics) Cash-to-Debt : 11.11 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Nanosonics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nanosonics's cash to debt ratio for the quarter that ended in Dec. 2023 was 11.11.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nanosonics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Nanosonics's Cash-to-Debt or its related term are showing as below:

NNCSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.62   Med: 31.51   Max: 138.54
Current: 11.11

During the past 13 years, Nanosonics's highest Cash to Debt Ratio was 138.54. The lowest was 2.62. And the median was 31.51.

NNCSF's Cash-to-Debt is ranked better than
73.81% of 840 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs NNCSF: 11.11

Nanosonics Cash-to-Debt Historical Data

The historical data trend for Nanosonics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nanosonics Cash-to-Debt Chart

Nanosonics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 138.47 35.19 38.54 8.07 10.46

Nanosonics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.41 8.07 8.67 10.46 11.11

Competitive Comparison of Nanosonics's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Nanosonics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanosonics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nanosonics's Cash-to-Debt falls into.


Nanosonics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nanosonics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=75.274 / (1.934 + 5.26)
=10.46

Nanosonics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=79.193 / (2.021 + 5.108)
=11.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanosonics  (OTCPK:NNCSF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nanosonics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nanosonics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanosonics (Nanosonics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (OTCPK:NNCSF) » Definitions » Cash-to-Debt
Comparable Companies
ASX:TRJ ASX:SDI ASX:AHC ASX:OSX ASX:ANN ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD OCSE:COLO B WST TSE:4543 XSWX:STMN XPAR:DIM BAX HOLX COO TSE:7733
Traded in Other Exchanges
OQS:Germany NAN:Australia
Address
7-11 Talavera Road, Level 1 Building A, Macquarie Park, Sydney, NSW, AUS, 2113
Website
https://www.nanosonics.com.au
Nanosonics is a single-product firm and its trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low temperature sonically activated hydrogen peroxide mist that is suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection across patients. Nanosonics' revenue is made up of capital sales of trophon units, ongoing consumables sales, and service revenue. At June 2022, there were 29,850 trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, roughly 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in Asia-Pacific.